Tag: 200-300

On March 31, 2022, Durner, Juergen; Schrickel, Klaus; Watts, David C.; Becker, Marc; Draenert, Miriam E. published an article.COA of Formula: C12H18O5 The title of the article was Direct and indirect eluates from bulk fill resin-based-composites. And the article contained the following:

To compare elutable substances directly released from bulk-fill (BF) resin-based composites (RBCs) with indirect elution from teeth restored with a BF composite. In addition to (co)monomers, the anal. focus was on other potentially toxic ingredients or impurities. Furthermore, the barrier function of the residual dentin/adhesive layer was studied.Six BF-RBC materials were studied. For each material subgroup, ten human third molar teeth with standard Class-I occlusal cavities were prepared and provided with a three-step adhesive system and the resp. composite restoration (tooth groups). Same sized control specimens of the restorative material were prepared (′direct BF-RBC′ groups). Each specimen was placed in an elution chamber such that the elution media (ethanol/water, 3:1) only contacted the tooth root or 3/4 height of each specimen. They were incubated at 37 °C for up to 7 d. Samples of eluate were taken after 1, 2, 4 and 7 d and were analyzed by high-temperature gas chromatog./mass spectrometry.(Co)monomers such as Bisphenol A ethoxylate dimethacrylate (bisEMA) or tetraethylene glycol dimethacrylate (TEEGDMA) were mostly found in the eluates of the ′direct BF-RBC′ groups in statistically significantly greater amounts than in the eluates of the ′tooth groups′. The residual dentin and/or adhesive layers acted as a diffusion barrier for most of the substances except for triethylene glycol dimethacrylate (TEGDMA) or diethylene glycol dimethacrylate (DEGDMA). For TEGDMA up to 3 orders of magnitude more were found in the ′tooth groups′ compared to the ′direct BF-RBC′ groups, evidently released by the adhesive system.Substances of Very High Concern (SVHC) including TINUVIN 328 and BPA were found mainly in the eluates of ′direct BF-RBC′ groups.For estimation of biocompatibility, a total system, specifically BF-RBC + adhesive, should always be investigated since individual considerations, such as only elution from a BF-RBC, do not correctly reflect the total clin. situation. The focus of elution tests should not only be on the co(monomers), but also on other ingredients or impurities that may be released. The experimental process involved the reaction of Oxybis(ethane-2,1-diyl) bis(2-methylacrylate)(cas: 2358-84-1).COA of Formula: C12H18O5

The Article related to fill resin composite eluate dental restoration, 328, bpa, bisema, bisphenol a ethoxylate dimethacrylate, bulk fill, decan-1,10-diol dimethacrylate, dentin barrier, dentinal tubules, dicyclohexyl phthalate, drometrizole, elution, gc/ms, tinuvin, tetraethylene glycol dimethacrylate and other aspects.COA of Formula: C12H18O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 20, 2021, Bi, Jingjing; Tan, Qiang; Wu, Hao; Liu, Qingfeng; Zhang, Guisheng published an article.Formula: C12H16O7 The title of the article was Rhodium-Catalyzed Denitrogenative Trans-annulation of N-Sulfonyl-1,2,3-triazoles with Glycals Giving Pyrroline-Fused N-Glycosides. And the article contained the following:

Described here is a selective synthesis of 2,3-dihydropyrrole-fused N-glycosides through rhodium-catalyzed denitrogenation trans-annulation of N-sulfonyl-1,2,3-triazoles with glycals. A series of pyrroline-fused N-glycosides are afforded in moderate to excellent yields with exclusive regioselectivity and stereoselectivity. Functional application of such a resultant product by oxidative addition and epoxidation is also explored. Notably, the treatment of a pyrroline-fused N-glycoside (3a) with TMSOTf efficiently leads to an interesting unexpected C-nucleoside I via a TMSOTf-inducing ring opening/acetyl migration/ring closing reaction sequence. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Formula: C12H16O7

The Article related to crystal structure aminoglycoside stereoselective cyclization sulfonyl triazole glycal, stereoselective cyclization aminoglycoside preparation rhodium catalyzed sulfonyl triazole glycal, aminoglycoside preparation rhodium catalyzed annulation sulfonyl triazole pyrroline glycoside and other aspects.Formula: C12H16O7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 8, 1998, Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C. published a patent.COA of Formula: C11H14N2O5 The title of the patent was Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists. And the patent contained the following:

The title compounds X-Y-Z-A-B [I; X = (un)substituted 5-7- membered aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered aromatic or nonaromatic ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered aromatic ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused aromatic ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepared and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).COA of Formula: C11H14N2O5

The Article related to phenoxyalkanoic acid preparation formulation fibrinogen antagonist, platelet aggregation inhibitor phenoxyalkanoic acid preparation, bone resorption inhibitor phenoxyalkanoic acid preparation, thrombus treatment phenoxyalkanoic acid preparation formulation, embolus treatment phenoxyalkanoic acid preparation formulation and other aspects.COA of Formula: C11H14N2O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 23, 2009, Shishkov, Igor V.; Rominger, Frank; Hofmann, Peter published an article.Synthetic Route of 29704-38-9 The title of the article was Remarkably stable copper(I) α-carbonyl carbenes: synthesis, structure, and mechanistic studies of alkene cyclopropanation reactions. And the article contained the following:

Copper(I) iminophosphinamido α-acylcarbene complexes were prepared by ligand substitution of η2-ethene complex with 2-aryl diazoacetate esters and diazoacetamides; crystal structure, thermal decomposition and cyclopropanation kinetics were examined Reaction of [[tBu2P(NSiMe3)2κN,κN’]Cu(η2-C2H4)] (1) with 4-R1C6H4C(N2)COR2 [7a-g; R1 = NO2, OMe; R2 = OEt, OtBu, NMe2, OMe, OCH(1,4-C6H4Cl)2] gave the corresponding carbene complexes [[tBu2P(NSiMe3)2κN,κN’]Cu:C(COR2)-1,4-C6H4R1] (8a-g) whereas 2-diazo-N,N-diisopropylacetamide was unreactive. The rotation barriers around the Cu-Ccarbene and Ccarbene-CAr bonds or their low limits were determined for some of these compounds by 1H-VT-NMR spectroscopy. Carbene 8g [R1 = OMe, R2 = OCH(p-Cl-C6H4)2] was isolated in anal. pure, crystalline form as the first stable representative of this important class of compounds Its solid-state mol. structure revealed an orthogonal position of the carbene fragment relative to both the ligand plane and the ester C:O group and a remarkably short Cu-Ccarbene distance of 1.822(4) Å. Compound 8g reacted with styrene stereoselectively to give the corresponding trans-cyclopropane derivative and [tBu2P(NSiMe3)2-κ2N]Cu(η2-CH2:CHPh). The stoichiometric cyclopropanation of styrene with 8g and the previously described diarylcarbene [[tBu2P(NSiMe3)2-κ2N]Cu:C(p-NO2C6H4)2] (6) in toluene-d8 revealed that the reactions are first order in both the copper carbenes and the alkene. The activation parameters for 8g (ΔH⧧ = 51.5(9) kJ mol-1 and ΔS⧧ = -127.1(28) J mol-1 K-1) and for 6 (ΔH⧧ = 53.4(8) kJ mol1- and ΔS⧧ = -152.1(23) J mol-1 K-1) were derived from the kinetics of the cyclopropanation processes. Thermal decomposition of carbene 8g in toluene-d8 displayed first-order kinetics until 20-25% conversion with activation parameters ΔH⧧ = 85.5(24) kJ mol-1 and ΔS⧧ = -49.0(76) J mol-1 K-1. Solutions of 6 in toluene-d8 also decompose in a first-order fashion with ΔH⧧ = 66.1(20) kJ mol-1 and ΔS⧧ = -125.5(56) J mol-1 K-1. A Hammett study employing 8g and para-substituted styrenes afforded ρ = -1.06(19), demonstrating the electrophilic nature of α-carbonyl copper(I) carbene (Fischer-type) complexes. The electronic structure of 8 with R1 = R2 = OMe was investigated by DFT methods. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Synthetic Route of 29704-38-9

The Article related to copper carbene acylcarbene carboxycarbene complex preparation cyclopropanation kinetics, thermal decomposition kinetics copper acylcarbene carboxycarbene complex, diazoacetate diazoacetamide aryl complexation copper carbene complex preparation structure, crystal structure copper iminophosphinamide acylcarbene complex and other aspects.Synthetic Route of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 4, 2021, Mei, Baicheng; Zhou, Yuxing; Schweizer, Kenneth S. published an article.Formula: C13H10O3 The title of the article was Experimental test of a predicted dynamics-structure-thermodynamics connection in molecularly complex glass-forming liquids. And the article contained the following:

Understanding in a unified manner the generic and chem. specific aspects of activated dynamics in diverse glass-forming liquids over 14 or more decades in time is a grand challenge in condensed matter physics, phys. chem., and materials science and engineering. Large families of conceptually distinct models have postulated a causal connection with qual. different ‘order parameters’ including various measures of structure, free volume, thermodn. properties, short or intermediate time dynamics, and mech. properties. Construction of a predictive theory that covers both the noncooperative and cooperative activated relaxation regimes remains elusive. Here, we test using solely exptl. data a recent microscopic dynamical theory prediction that although activated relaxation is a spatially coupled local-nonlocal event with barriers quantified by local pair structure, it can also be understood based on the dimensionless compressibility via an equilibrium statistical mechanics connection between thermodn. and structure. This prediction is found to be consistent with observations on diverse fragile mol. liquids under isobaric and isochoric conditions and provides a different conceptual view of the global relaxation map. As a corollary, a theor. basis is established for the structural relaxation time scale growing exponentially with inverse temperature to a high power, consistent with experiments in the deeply supercooled regime. A criterion for the irrelevance of collective elasticity effects is deduced and shown to be consistent with viscous flow in low-fragility inorganic network-forming melts. Finally, implications for relaxation in the equilibrated deep glass state are briefly considered. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Formula: C13H10O3

The Article related to dynamics structure thermodn molecularly complex glass forming liquid, glass former supercooled liquid dynamics structure thermodn, supercooled liquid dynamics structure thermodn glass transition, activated relaxation, fragile-to-strong crossover, glass transition, molecular liquids, thermodynamics–dynamics connection and other aspects.Formula: C13H10O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Cermak, Vladimir; Trnecka, Vladimir published an article in 1980, the title of the article was Photopolymer compounds with a higher degree of flexibility. II. Compounds based upon epoxyacrylates.Quality Control of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate) And the article contains the following content:

All cured epoxy-acrylate compositions based on epoxy resin ChS 15 [25068-38-6] and various acrylates had a higher flexibility and lower hardness than epoxy-methacrylate compositions Of the several acrylate monomers studied, only 2-ethylhexyl acrylate (I) [103-11-7] at concentration >20% exhibited a plasticizing influence. The composition having the best mech. properties and a high curing rate contained 10% I and 20% trimethylolpropane triacrylate [15625-89-5]. Diacrylates did not significantly affect the mech. properties. of the compositions but favorably influenced their viscosity. The experimental process involved the reaction of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)(cas: 1985-51-9).Quality Control of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)

The Article related to epoxy acrylate composition flexibility hardness, methacrylate epoxy composition flexibility hardness, ethylhexyl acrylate epoxy composition, flexibility epoxy acrylate photopolymerized composition, trimethylolpropane triacrylate photopolymerization composition, photopolymerization composition epoxy acrylate and other aspects.Quality Control of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 18, 2007, Sugita, Kazuyuki; Otsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Itoh, Masao published a patent.Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis. And the patent contained the following:

The title compounds I [R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compounds of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to pyrrolobenzoxazepine derivative analog preparation hypercholesteremia hyperlipemia arteriosclerosis treatment, squalene synthetase cholesterol synthesis inhibitor pyrrolobenzoxazepine derivative analog preparation, tricyclic compound preparation hypercholesteremia hyperlipemia arteriosclerosis treatment and other aspects.Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 4, 2008, Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ito, Masao published a patent.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis. And the patent contained the following:

The title compounds [I; R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compounds of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to pyrrolobenzoxazepine derivative analog preparation hypercholesteremia hyperlipemia arteriosclerosis treatment, squalene synthetase cholesterol synthesis inhibitor pyrrolobenzoxazepine derivative analog preparation, tricyclic compound preparation hypercholesteremia hyperlipemia arteriosclerosis treatment and other aspects.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 10, 2004, Fujimoto, Roger Aki; McQuire, Leslie Wighton; Monovich, Lauren G.; Mugrage, Benjamin Biro; Parker, David Thomas; Van Duzer, John Henry; Wattanasin, Sompong published a patent.Formula: C12H14F3NO2 The title of the patent was Preparation of substituted amino phenylacetic acids and derivatives and their use as cyclooxygenase-2 (COX-2) inhibitors. And the patent contained the following:

The title compounds I (R = H, alkyl, cycloalkyl, halo, alkoxy, F3CO, Me3C, cyano, R1 = biaryl, β-naphthyl derivative, bicyclic heterocyclic aryl, cycloalkyl monocyclic carbocyclic aryl, cycloalkane fused-monocyclic carbocyclic aryl) were prepared Thus, N,N-dimethyl-2-(2′,3′,5′,6′-tetrafluoro-4′-phenylanilino)phenylacetamide was hydrolyzed to give I (R = H, R1 = 4-PhC6F4). The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Formula: C12H14F3NO2

The Article related to phenylacetic acid amino preparation cyclooxygenase 2 inhibitor, rheumatoid arthritis inhibitor aminophenylacetic acid, osteoarthritis inhibitor aminophenylacetic acid, dysmenorrhea inhibitor aminoophenylacetic acid, pain inhibitor aminophenylacetic acid, neoplasm inhibitor aminophenylacetic acid, inflammation inhibitor aminophenylacetic acid and other aspects.Formula: C12H14F3NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 4, 2016, Dejesus, Reynalda K.; Fu, Qinghong; Jiang, Jinlong; Tang, Haifeng published a patent.Synthetic Route of 1198284-94-4 The title of the patent was Preparation of novel spirocyclic compounds as inhibitors of the renal outer medullary potassium channel. And the patent contained the following:

The title compounds I [R1 = H, halo, OH, alky, alkoxy; R2 = H, alkyl; R3 = H, or alkyl optionally substituted with OH, OMe or 1-3 halo; or R3 and R4 are joined together to form CH2CH2; R4 = H, or alkyl optionally substituted with OH, OMe or 1-3 halo; n = 1-2; m = 1-2, wherein when m = 2, X3 = CH2; R5 = H, halo, cycloalkyl or alkyl; X1 = C(O), CH2; X2 = O, CH2; X3 = C(O), CH2, wherein when X3 = CH2, m = 2;X4 = C(O), SO2; Z = II or III (Y1-Y4 = (independently) CR9 or N; provided that at most two of Y1-Y4 are N; R9 = (independently) H, halo, alkoxy or alkyl optionally substituted with 1-3 halo; R10 = H, halo, alkyl optionally substituted with 1-3 halo; R11 = H, alkyl optionally substituted with 1-3 halo; R12 = H or alkyl)] which are inhibitors of the ROMK (Kir1.1) channel, were prepared For example, microwaving a solution of (1R,3r,5S)-1′-(2-methyl-3-oxocyclopent-1-en-1-yl)-8-azaspiro[bicyclo[3.2.1]octane-3,3′- pyrrolidin]-2′-one and (R)-4-methyl-5-(oxiran-2-yl)isobenzofuran- 1(3H)-one in EtOH at 145°C for 4.5 h afforded IV. Exemplified compounds I were tested in the thallium flux assay (data given). The compounds I may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions comprising I, alone or in combination with other therapeutic agent, are disclosed. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Synthetic Route of 1198284-94-4

The Article related to spirocyclic compound preparation renal outer medullary potassium channel inhibitor, romk inhibitor diuretic natriuretic cardiovascular antihypertensive spirocyclic compound preparation, heart failure chronic kidney disease treatment spirocyclic compound preparation, excessive salt water retention treatment spirocyclic compound preparation and other aspects.Synthetic Route of 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics